西酞普兰联合奥氮平治疗抑郁的临床疗效及对认知功能的影响

doi:10.3969/j.issn.1006-6233.2018.10.017

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1293 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨西酞普兰联合奥氮平治疗抑郁的临床疗效及对认知功能的影响。方法: 选取我科在2017年2月至2018年6月门诊的抑郁症患者100例,随机分为两组,研究组使用西酞普兰30mgQD联合奥氮平1.25~2.25mgQN治疗,对照组单用西酞普兰30mgQD治疗,并分别予以HAMD-17项抑郁量表、PSQI睡眠量表及LOTCA认知功能成套测验比较分析两组患者治疗后临床疗效、睡眠改善程度及认知功能评分。结果:研究组临床症状改善显著优于对照组(P<0.05);研究组患者睡眠质量改善早于对照组并显著优于对照组(P<0.05);研究组治疗后多项认知功能评分优于对照组(P<0.05);研究组不良反应发生率与对照组无显著差异(P>0.05)。结论:在对中重度抑郁症患者的治疗过程当中,西酞普兰联合奥氮平治疗效果较好,为临床治疗提供新思路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	范川
	杨平

关键词 ：抑郁障碍, 西酞普兰, 奥氮平, 临床疗效分析, 认知功能

Abstract：Objective: To explore the clinical efficacy of citalopram and olanzapine in the treatment of depression and its effects on cognitive function.Methods: Select 100 patients with depression from February 2017 to June 2018 in our hospital.Patients were randomly divided into two groups, the patients in the study group were treated with citalopram combined with olanzapine and thepatients in the control group was treated with only citalopram. The clinical efficacy and cognitive function of the two groups were compared after theropy.Results: The clinical efficacy of the study group was better than that of the control group (P< 0.05). The sleeping quality of the patients in the study group was significantly better than that of the control group (P<0.05). The cognitive function of the group was better than that of the control group (P<0.05).There was noh no statistic difference in the incidence of adverse reactions between the study group and the control group(P>0.05).Conclusion: In the treatment of patients with depression, the effect of citalopram combined with olanzapine is ideal, which should be further popularized in clinic.

Key words： Depression Citalopram Olanzapine Clinical efficacy analysis Cognitive function

基金资助:安徽省高等学校自然科学研究重点项目,(编号:KJ2018A0659)

通讯作者: 杨平

引用本文:

范川,杨平. 西酞普兰联合奥氮平治疗抑郁的临床疗效及对认知功能的影响[J]. 河北医学, 2018, 24(10): 1651-1655.
FAN Chuan, et al. Clinical Efficacy of Citalopram Combined with Olanzapine in the Treatment of Depression and its Effects on Cognitive Function. HeBei Med, 2018, 24(10): 1651-1655.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.10.017 或 http://www.hbyxzzs.cn/CN/Y2018/V24/I10/1651

[1] Perlman K,Benrimoh D,Israel S,et al.A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder[J].Journal of Affective Disorders,2018,9(243):503~515.
[2] Ulbricht C M, Dumenci L, Rothschild A J, et al. Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis[J]. Archives of Womens Mental Health, 2016, 19(5):769~778.
[3] Wright BM, Eiland EH 3rd,Lorenz R.Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature[J].Pharmacotherapy,2013,33(3):344~359.
[4] Bingham K S, Rothschild A J, Mulsant B H, et al. The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression[J]. Journal of Clinical Psychiatry, 2017, 24(3):S103~S104.
[5] Cipriani A, Furukawa T A, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis[J]. Lancet, 2018, 391(10128):1357~1366.
[6] Wagner G, Schultes MT,Titscher V,et al.Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis[J].Journal of Affective Disorders,2018,3(228):1~12.
[7] Liu Bangshan,Liu Jin, Wang Mi,et al.From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder[J].Frontiers in Cellular Neuroscience,2017,9(11):305
[8] E Pereira, F Coutinho, M Marinho, et al. The role of augmentation treatment with second-generation antipsychotics in major depression disorder-current evidence in the literature[J]. European Psychiatry, 2016, 33(3):S159~S160.
[9] Pennybaker SJ,Niciu MJ, Luckenbaugh DA,et al.Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion[J].Journal of Affective Disorders,2017,1(208):560~566.
[10] Monti JM.The effect of second-generation antipsychotic drugs on sleep parameters in patients with unipolar or bipolar disorder[J].Sleep Medicine,2016,7(23):89~96.
[11] Steiner A J, Boulos N, Wright S M, et al. Major depressive disorder in patients with doctoral degrees: patient-reported depressive symptom severity, functioning, and quality of life before and after initial treatment in the STAR*D study[J]. Journal of Psychiatric Practice, 2017, 23(5):328~341.
[12] 赵瑾,张燕,晁阳阳,等.利培酮和奥氮平对首发精神分裂症患者治疗前后认知功能的对比观察[J].中华医学杂志,2016,96(37):2960~2964.
[13] Farooq S,Singh SP.Fixed dose-combination products in psychiatry: Systematic review and meta-analysis[J]. Journal of Psychopharmacology, 2015,29(5):556~564.